SCHEMBL5160875

SCHEMBL5160875

COC(=O)CC(=O)c1cn[nH]c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 1/20 0.38
ACACB O00763 3/20 0.37
NOS2 P35228 1/20 0.37
BAZ2B Q9UIF8 1/20 0.37
BAZ2A Q9UIF9 1/20 0.37
HTT P42858 1/20 0.36
MGAM O43451 1/20 0.35
GAA P10253 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35
ROCK2 O75116 2/20 0.34
ROCK1 Q13464 2/20 0.34
KCNH2 Q12809 1/20 0.34
NAMPT P43490 1/20 0.34
ADORA2B P29275 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5162787 0.84 KMT2A (0.53) MEN1KMT2AALDH1A1KDM4EACACB
SCHEMBL5160415 0.83 ALDH1A1 (0.35) ALDH1A1KDM4EACACBNOS2HTT
SCHEMBL5158384 0.83 ACACB (0.41) MEN1KMT2AALDH1A1ACACBNOS2
SCHEMBL20797184 0.81 ALDH1A1 (0.38) MEN1KMT2AALDH1A1KDM4EACACB
SCHEMBL5161535 0.80 ALDH1A1 (0.39) ALDH1A1ACACBNOS2BAZ2BBAZ2A
SCHEMBL5178020 0.79 NOS2 (0.38) ALDH1A1ACACBNOS2HTTROCK1
SCHEMBL5163553 0.79 ACACB (0.38) ALDH1A1ACACBNOS2HTTROCK2
SCHEMBL8402539 0.79
SCHEMBL5158160 0.77 ACACB (0.37) ALDH1A1KDM4EACACBNOS2BAZ2B
SCHEMBL420023 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO MEN1 4424/4885KMT2A 1666/4885ALDH1A1 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.